1. Home
  2. FERA vs SLP Comparison

FERA vs SLP Comparison

Compare FERA & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FERA
  • SLP
  • Stock Information
  • Founded
  • FERA 2024
  • SLP 1996
  • Country
  • FERA Cayman Islands
  • SLP United States
  • Employees
  • FERA N/A
  • SLP N/A
  • Industry
  • FERA
  • SLP EDP Services
  • Sector
  • FERA
  • SLP Technology
  • Exchange
  • FERA Nasdaq
  • SLP Nasdaq
  • Market Cap
  • FERA 317.4M
  • SLP 286.6M
  • IPO Year
  • FERA 2025
  • SLP 1997
  • Fundamental
  • Price
  • FERA $10.15
  • SLP $14.57
  • Analyst Decision
  • FERA
  • SLP Buy
  • Analyst Count
  • FERA 0
  • SLP 7
  • Target Price
  • FERA N/A
  • SLP $29.50
  • AVG Volume (30 Days)
  • FERA 103.0
  • SLP 420.9K
  • Earning Date
  • FERA 01-01-0001
  • SLP 07-14-2025
  • Dividend Yield
  • FERA N/A
  • SLP N/A
  • EPS Growth
  • FERA N/A
  • SLP N/A
  • EPS
  • FERA N/A
  • SLP N/A
  • Revenue
  • FERA N/A
  • SLP $80,383,000.00
  • Revenue This Year
  • FERA N/A
  • SLP $15.28
  • Revenue Next Year
  • FERA N/A
  • SLP $0.79
  • P/E Ratio
  • FERA N/A
  • SLP N/A
  • Revenue Growth
  • FERA N/A
  • SLP 20.01
  • 52 Week Low
  • FERA $10.00
  • SLP $12.39
  • 52 Week High
  • FERA $10.60
  • SLP $37.72
  • Technical
  • Relative Strength Index (RSI)
  • FERA N/A
  • SLP 50.24
  • Support Level
  • FERA N/A
  • SLP $13.70
  • Resistance Level
  • FERA N/A
  • SLP $14.88
  • Average True Range (ATR)
  • FERA 0.00
  • SLP 0.58
  • MACD
  • FERA 0.00
  • SLP 0.29
  • Stochastic Oscillator
  • FERA 0.00
  • SLP 86.28

About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares

Fifth Era Acquisition Corp I is a blank check company.

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Share on Social Networks: